PI3K-mTOR in Cancer and Cancer Therapy
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target g
- PDF / 5,658,519 Bytes
- 307 Pages / 467.717 x 683.15 pts Page_size
- 21 Downloads / 216 Views
Nandini Dey Pradip De Brian Leyland-Jones Editors
PI3K-mTOR in Cancer and Cancer Therapy Foreword by Matthew J. Ellis
Cancer Drug Discovery and Development Series editor Beverly A. Teicher Bethesda, Maryland, USA
Cancer Drug Discovery and Development, the Springer series headed by Beverly A. Teicher, is the definitive book series in cancer research and oncology. Volumes cover the process of drug discovery, preclinical models in cancer research, specific drug target groups, and experimental and approved therapeutic agents. The volumes are current and timely, anticipating areas where experimental agents are reaching FDA approval. Each volume is edited by an expert in the field covered, and chapters are authored by renowned scientists and physicians in their fields of interest.
More information about this series at http://www.springer.com/series/7625
Nandini Dey Pradip De Brian Leyland-Jones •
Editors
PI3K-mTOR in Cancer and Cancer Therapy
Foreword by Matthew J. Ellis
Editors Nandini Dey Avera Cancer Institute Center for Precision Oncology Sioux Falls, SD USA
Brian Leyland-Jones Avera Cancer Institute Center for Precision Oncology Sioux Falls, SD USA
Pradip De Avera Cancer Institute Center for Precision Oncology Sioux Falls, SD USA
ISSN 2196-9906 ISSN 2196-9914 (electronic) Cancer Drug Discovery and Development ISBN 978-3-319-34209-2 ISBN 978-3-319-34211-5 (eBook) DOI 10.1007/978-3-319-34211-5 Library of Congress Control Number: 2016939046 © Springer Science+Business Media New York 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Humana Press imprint is published by Springer Nature The registered company is Springer International Publishing AG Switzerland
To the past, present and future patients of Avera Cancer Institute
Foreword
Analysis of the genomic landscape of cancer over the last half decade through next generation sequencing (NGS) studies has revealed a diverse array of somatic mutations that activate the phosphoinositol
Data Loading...
